Custom Cancer Insurance And Digital Underwriting Will Drive Future Expansion

Published
06 Aug 24
Updated
06 Aug 25
AnalystConsensusTarget's Fair Value
US$107.23
3.4% undervalued intrinsic discount
06 Aug
US$103.55
Loading
1Y
1.8%
7D
4.7%

Author's Valuation

US$107.2

3.4% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on07 May 25
Fair value Increased 10%

Shared on30 Apr 25
Fair value Increased 2.28%

AnalystConsensusTarget has decreased shares outstanding growth rate from -0.0% to -0.0%.

Shared on23 Apr 25
Fair value Increased 0.042%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on16 Apr 25
Fair value Decreased 0.68%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Increased 0.89%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Decreased 9.78%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Decreased 2.12%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on10 Mar 25
Fair value Decreased 9.54%